I agree that this site is using cookies. You can find further informations here.
X
The REMAP-CAP Investigators
25  results:
?
1

Simvastatin in Critically Ill Patients with Covid-19:

REMAP-CAP Investigators ; Hills, Thomas E ; Lorenzi, Elizabeth...
https://www.repository.cam.ac.uk/handle/1810/363268.  , 2023
Link: https://www.repository.c..
 
?
2

Coronavirus disease 2019 subphenotypes and differential tre..:

Fish, M. ; Rynne, J. ; Jennings, A....
Intensive Care Medicine.  48 (2022)  11 - p. 1525-1538 , 2022
Link: https://doi.org/10.1007/..
 
?
3

Effect of Antiplatelet Therapy on Survival and Organ Suppor..:

REMAP-CAP Writing Committee for the REMAP-CAP Investigators
JAMA. 2022.  , 2022
Link: http://hdl.handle.net/10..
 
?
4

Virological Characterization of Critically Ill Patients Wit..:

Ratcliff, Jeremy ; Nguyen, Dung ; Fish, Matthew...
The Journal of Infectious Diseases.  224 (2021)  4 - p. 595-605 , 2021
Link: https://doi.org/10.1093/..
 
?
5

Interleukin-6 Receptor Antagonists in Critically Ill Patien..:

The REMAP-CAP Investigators ; Gordon, A ; Mouncey, P...
http://hdl.handle.net/10044/1/90567.  , 2021
Link: http://hdl.handle.net/10..
 
?
6

Effect of Antiplatelet Therapy on Survival and Organ Suppor..:

Investigators, REMAP-CAP Writing Committee for the REMAP-CAP ; Dark, Paul
Investigators , REMAP-CAP W C F T REMAP-CAP & Dark , P 2022 , ' Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. ' , JAMA , vol. 327 , no. 13 , pp. 1247-1259 . https://doi.org/10.1001/jama.2022.2910.  , 2022
Link: https://research.manches..
 
?
7

Interleukin-6 Receptor Antagonists in Critically Ill Patien..:

Felton, Timothy ; Dark, Paul
REMAP-CAP Investigators , Felton , T & Dark , P 2021 , ' Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 ' , The New England Journal of Medicine , vol. 384 , no. 16 , pp. 1491-1502 . https://doi.org/10.1056/NEJMoa2100433.  , 2021
Link: https://research.manches..
 
?
8

Correction to: Implementation of the Randomized Embedded Mu..:

The UPMC REMAP-COVID Group, on behalf of the REMAP-CAP Investigators
Trials.  22 (2021)  1 - p. , 2021
Link: https://doi.org/10.1186/..
 
?
9

Implementation of the Randomized Embedded Multifactorial Ad..:

The UPMC REMAP-COVID Group, on behalf of the REMAP-CAP Investigators
Trials.  22 (2021)  1 - p. , 2021
Link: https://doi.org/10.1186/..
 
?
10

Therapeutic Anticoagulation with Heparin in Critically Ill ..:

Goligher, Ewan C ; Bradbury, Charlotte A ; McVerry, Bryan J...
qt0w99982h.  , 2021
Link: https://escholarship.org..
 
?
11

Therapeutic Anticoagulation with Heparin in Noncritically I..:

Lawler, Patrick R ; Goligher, Ewan C ; Berger, Jeffrey S...
qt52q469xv.  , 2021
Link: https://escholarship.org..
 
?
12

Lopinavir-ritonavir and hydroxychloroquine for critically i..:

Arabi, Yaseen M ; Gordon, Anthony C ; Derde, Lennie PG...
qt997793pw.  , 2021
Link: https://escholarship.org..
 
?
13

Therapeutic Anticoagulation with Heparin in Noncritically I..:

Investigators, REMAP-CAP ; Dark, Paul
Investigators , REMAP-CAP & Dark , P 2021 , ' Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. ' , The New England Journal of Medicine , vol. 385 , no. 9 , pp. 790-802 . https://doi.org/10.1056/NEJMoa2105911.  , 2021
Link: https://research.manches..
 
?
14

Lopinavir-ritonavir and hydroxychloroquine for critically i..:

Investigators, REMAP-CAP ; Dark, Paul
Investigators , REMAP-CAP & Dark , P 2021 , ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. ' , Intensive care medicine , vol. 47 , no. 8 , pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5.  , 2021
Link: https://research.manches..
 
?
15

Correction to: Implementation of the Randomized Embedded Mu..:

The UPMC REMAP-COVID Group ; on behalf of the REMAP-CAP Investigators
https://doi.org/10.1186/s13063-021-05109-8.  , 2021
Link: https://doi.org/10.1186/..
 
1-15